Lasofoxifene Shows Promise in Early Breast Cancer Treatment, I-SPY 2 Trial Data Reveal
Lasofoxifene demonstrates a strong tolerability profile and promising Ki67 suppression in a Phase 2 study, supporting further exploration in the neoadjuvant setting.